You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華大基因(300676.SZ):中標不低於1.348億元的罕見病患者全基因組測序項目
格隆匯 06-02 22:05

格隆匯6月2日丨華大基因(300676.SZ)公佈,公司全資子公司武漢華大醫學檢驗所有限公司(以下簡稱漢醫檢所)近日收到採購代理機構四川國際招標有限責任公司的《中標通知書》項目的採購人為四川大學華西醫院,通知書確認武漢醫檢所四川大學華西醫院十萬例罕見病患者全基因組測序計劃採購項目(項目編號SCIT-ZGZ-2021040009/1)的中標單位。

項目中標金額人民1348/服務例數不低於十萬例合同期簽訂後,三個月內完成首台設備的安裝、調試、標準品測試、測序數據分析流程搭建及測序試運行;送檢每一批樣品質檢合格後20個工作日內完成所有服務內容(全基因組WGS建庫和測序)。

明確罕見病致病基因,對促進疾病診斷、臨牀治療均具有重要意義項目是華西醫院計劃通過全基因組檢測和分析整合臨牀診療信息開發罕見病疑難病臨牀智能決策支持系統,協助醫生進行臨牀疑難病的診斷和治療。公司作為全球領先的科學技術服務提供商和精準醫療服務運營商致力於將前沿的基因領域科研成果及生物技術應用於民生健康等相關領域,推動基因科技成果的產業化。公司參與本項目中標及後續實施,有助於推動基因科技支持臨牀科研發展助力維護罕見病患者的健康權益有利於進一步提升和鞏固公司在行業及市場領先地位。

根據《中標通知書》武漢醫檢所將在中標通知書發出之日起30 日內採購人簽訂合同。此次武漢醫檢所中標金額不低於人民幣13480萬元(以項目全部順利執行交付完畢為前提),佔公司2020營業收入1.61%能簽訂正式項目合同並順利實施,將對公司未來經營業績產生積極影響

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account